Ingrid Jenny Guldvik

  • PhD student
 

Original articles

Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, Connell SP, Mills IG, Brewer DS, Mills R, Cooper CS, Clark J (2019)
Methodology for the at-home collection of urine samples for prostate cancer detection
Biotechniques, 68 (2), 65-71
DOI 10.2144/btn-2019-0092, PubMed 31779479

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I, Movember GAP1 Urine Biomarker Consortium, Parker C, Brewer DS, Cooper CS, Clark J (2019)
A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients
BJU Int, 124 (4), 609-620
DOI 10.1111/bju.14811, PubMed 31106513

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Askheim OP, Christensen K, Fluge S, Guldvik I (2017)
User participation in the Norwegian Welfare Context: an Analysis of Policy Discourses
J. Soc. Policy, 46 (3), 583-601

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG (2017)
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728

Bollineni RC, Guldvik IJ, Grönberg H, Wiklund F, Mills IG, Thiede B (2015)
A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate
Analyst, 140 (24), 8109-17
DOI 10.1039/c5an01560j, PubMed 26541119

Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG (2014)
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Oncogene, 34 (28), 3744-50
DOI 10.1038/onc.2014.307, PubMed 25241896

Engedal N, Torgersen ML, Guldvik IJ, Barfeld SJ, Bakula D, Sætre F, Hagen LK, Patterson JB, Proikas-Cezanne T, Seglen PO, Simonsen A, Mills IG (2013)
Modulation of intracellular calcium homeostasis blocks autophagosome formation
Autophagy, 9 (10), 1475-90
DOI 10.4161/auto.25900, PubMed 23970164

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Cancer Res, 73 (16), 5277-87
DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
J Immunother, 34 (5), 438-47
DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Perander M, Aberg E, Johansen B, Dreyer B, Guldvik IJ, Outzen H, Keyse SM, Seternes OM (2008)
The Ser(186) phospho-acceptor site within ERK4 is essential for its ability to interact with and activate PRAK/MK5
Biochem J, 411 (3), 613-22
DOI 10.1042/BJ20071369, PubMed 18248330

Page visits: 1864